Abstract 4048
Background
Contrast enhancement (CE) is described in 10-60% of low grade gliomas (LGG). Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is unknown. The aim of this study is to investigate whether CE is associated with molecular characteristics of LGG and elucidate its prognostic value.
Methods
All confirmed histological cases of LGG diagnosed in a single institution between years 2000-2016 were retrospectively reviewed (n = 104). Clinical, radiological and molecular factors were collected. Spinal and brainstem localization, only-biopsied tumours with ring-like enhancement and incomplete medical records were excluded. 1p/19 codeletion analysis was performed by FISH, IDH was performed by immunohistochemistry. IDH wild-type tumours were confirmed with qPCR. Overall survival (OS) was estimated by Kaplan-Meier method.
Results
We included 89 patients, with a median follow-up of 73.3 months. Mean age was 41.6 years, and 65.2% were male. CE was present on 25.8% of preoperative MRI, and 25.3% of patients were considered high-risk according to Pignatti score. Most were astrocytomas (67.4%) and 84.4% were surgically removed. IDH mutation was found in 66.7% of tumour samples, and 17.9% had a 1p/19q codeletion. No differences were observed amongst CE and non-CE groups, apart from age (46.6 vs 39.9 years, respectively; p = 0.041). IDH mutation (p = 0.776) and 1p/19q codeletion (p = 0.512) were evenly distributed. On univariate analysis, size >6cm (p = 0.002), CE (p = 0.026), extent of resection (p = 0.008), Pignatti score (p = 0.002) and IDH mutation (p = 0.003) were significantly associated to OS. On multivariate analysis, only CE (p = 0.009) and IDH status (p = 0.005) were independently associated to OS.
Conclusions
CE in LGG provides complementary and independent prognostic information to IDH and 1p/19q codeletion. Its contribution to treatment decisions requires further exploration in larger prospective cohort studies.
Clinical trial identification
Legal entity responsible for the study
Unidad de Neuro-Oncología, Institut Català d'Oncologia.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract